436 related articles for article (PubMed ID: 27185079)
1. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
[TBL] [Abstract][Full Text] [Related]
2. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
3. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
Noda H; Noguchi S; Yoshimine T; Goji S; Adachi K; Tamura Y; Izawa S; Ebi M; Yamamoto S; Ogasawara N; Funaki Y; Sasaki M; Kasugai K
J Gastrointestin Liver Dis; 2016 Sep; 25(3):283-8. PubMed ID: 27689190
[TBL] [Abstract][Full Text] [Related]
4. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
6. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
8. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
[TBL] [Abstract][Full Text] [Related]
10. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
11. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Kusano C; Gotoda T; Suzuki S; Ikehara H; Moriyama M
J Gastroenterol; 2018 Jun; 53(6):718-724. PubMed ID: 29110085
[TBL] [Abstract][Full Text] [Related]
12. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
Nishida T; Tsujii Y; Okamoto A; Tomita R; Higaki Y; Osugi N; Sugimoto A; Takahashi K; Mukai K; Nakamatsu D; Matsubara T; Hayashi S; Yamamoto M; Nakajima S; Fukui K; Inada M
Digestion; 2020; 101(5):608-614. PubMed ID: 31288235
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Liou JM; Chen CC; Chang CY; Chen MJ; Chen CC; Fang YJ; Lee JY; Yang TH; Luo JC; Wu JY; Liou TC; Chang WH; Hsu YC; Tseng CH; Chang CC; Bair MJ; Liu TY; Hsieh CF; Tsao FY; Shun CT; Lin JT; Lee YC; Wu MS;
Gut; 2016 Nov; 65(11):1784-1792. PubMed ID: 26338825
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
[TBL] [Abstract][Full Text] [Related]
18. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]